Also, regarding HyBryte (TM), in October 2024, Soligenix announced that the Hong Kong Patent Office had granted the patent entitled "Systems and Methods for Producing Synthetic Hypericin." Synthetic ...

Wānaka resident and multiple myeloma blood cancer patient Emma Holden, 36, will soon travel to Shanghai, China for ...

Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes ...

In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of ...

In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of ...

Sellas Life Sciences has reported the multicentre Phase IIa trial data of a highly selective cyclin-dependent kinase 9 (CDK9) ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

From crippling fatigue to brain fog, CML treatment can affect your body in ways that go beyond the usual side effects.

SELLAS Life Sciences Group (NASDAQ:SLS) announced on Thursday promising mid-stage trial results for SLS009, a highly ...

Hundreds of people in England with aggressive blood cancer are set to benefit from an innovative new treatment that reprogrammes a patient’s own immune cells to fight the disease after it was ...

Bristol Myers' Opdivo improved overall survival in resectable NSCLC, per final Phase 3 data. The study confirms its benefit when combined with chemotherapy.

We recently published a list of 10 Stocks Kick Off Trading Week With Losses. In this article, we are going to take a look at ...